Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
Georg Lenz(Charité - Universitätsmedizin Berlin), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Andreas Neubauer(RWTH Aachen University), Martin Dreyling(LMU Klinikum), Ali Aldaoud(Klinikum Braunschweig), Hartmut Eimermacher(St. Marien Hospital), Sonja Martin(Klinikum Braunschweig), E. Heidemann(Klinikum Braunschweig), Ulrich Dührsen(Essen University Hospital), Joerg Hasford(Ludwig-Maximilians-Universität München), Hjalmar B. Steinhauer(Klinikum Braunschweig), Hannes Wandt(Nuremberg Hospital), Michael Unterhalt, Bernhard Wörmann(Charité - Universitätsmedizin Berlin), Bernd Metzner(Klinikum Oldenburg), Reza Parwaresch(Klinikum Braunschweig), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 573
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
|New England Journal of Medicine|2010|1.3k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Diagnostic criteria and classification of mastocytosis: a consensus proposal
|Leukemia Research|2001|1.1k